Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israeli-based Teva Pharmaceutical Industries has been granted tentative approval to market a generic version of Abbott Laboratories' Depakote tablets in the US.
Subscribe to our email newsletter
The FDA approval, which is not expected to be final until 2008 when Abbott’s patent expires, is for Divalproex, a sodium delayed-release tablet to be produced in three different strengths.
Upon final approval, Teva’s Divalproex will be the AB-rated generic equivalent of Abbott’s Depakote tablets. This product is indicated for treatment of manic episodes associated with bipolar disorder, prophylaxis of migraine headaches, and as therapy in several types of epileptic disorders.
According to Teva, Depakote produces annual sales of approximately $813 million.